Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00673010 · ClinicalTrials.gov registry record · Phase 1
Lesion Dosimetry With 124-Iodine in Metastatic Thyroid Carcinoma
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT00673010: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00673010 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00673010, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
One of the most effective treatments for metastases from thyroid cancer is a form of radioactive iodine known as 131-I. For more than 50 years, 131-I has been used to find and destroy thyroid cancer cells that have spread to other parts of the body. In many cases this treatment destroys the metastatic cells. However, in some patients it does not appear to work completely. This study is designed to use a slightly different form of radioactive iodine (called 124-I) which can precisely predict the amount of radiation that each metastatic lesion will receive. 124-I was developed at Memorial Sloan-Kettering in the 1950s and has been used here and at many other medical centers around the world for diagnostic studies. It has been found to be very safe and effective at finding metastatic lesions. The high resolution of newer PET scanners now allows us to carefully determine how much radiation each metastatic lesion will receive. If 124-I can accurately predict which patients will not respond to 131-I treatments we can then avoid exposing those patients to unnecessary radiation. For the rest of the patients we can custom tailor the 131-I dose to destroy the metastatic lesions.
Interventions
- RADIATION 131 I-iodine (131-I), 124 I-iodine (124-I)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2005-03-07 |
| Est. Completion | 2025-10-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00673010
The ClinicalTrials.gov registry entry for NCT00673010 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 131 I-iodine (131-I), 124 I-iodine (124-I) is the first listed.
NCT00673010 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00673010 about?
NCT00673010 is a clinical study titled "Lesion Dosimetry With 124-Iodine in Metastatic Thyroid Carcinoma". One of the most effective treatments for metastases from thyroid cancer is a form of radioactive iodine known as 131-I. For more than 50 years, 131-I has been used to find and destroy thyroid cancer cells that have spread to other parts of the body. In many cases this treatment destroys the metastat...
What is the current status of trial NCT00673010?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2005-03-07. Estimated completion is 2025-10-02.
What interventions are being tested in trial NCT00673010?
The interventions under investigation include: 131 I-iodine (131-I), 124 I-iodine (124-I) (RADIATION).
Who is sponsoring clinical trial NCT00673010?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.